Negative Results

A genome-wide association study of plasma phosphorylated tau181

Jodie Lord\textsuperscript{a}, Anna Zettergren\textsuperscript{b}, Nicholas J. Ashton\textsuperscript{c,d,e,f}, Thomas K. Karikari\textsuperscript{c}, Andrea L. Benedet\textsuperscript{c}, Joel Simrén\textsuperscript{c,h}, the Alzheimer’s Disease Neuroimaging Initiative\textsuperscript{2}, for the AddNeuroMed consortium; Abdul Hye\textsuperscript{e,g}, Dag Aarsland\textsuperscript{e,g}, Kaj Blennow\textsuperscript{c,h}, Henrik Zetterberg\textsuperscript{c,h,i,j,1,*}, Petroula Proitsi\textsuperscript{a,1,*}

\textsuperscript{a} Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
\textsuperscript{b} Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (ACECAP) at the University of Gothenburg, Gothenburg, Sweden
\textsuperscript{c} Department of Psychiatry and Neurochemistry, Institute of Neuroscience \& Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
\textsuperscript{d} Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
\textsuperscript{e} Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
\textsuperscript{f} NIHR Biomedical Research Centre for Mental Health \& Biomedical Research Unit for Dementia at South London \& Maudsley NHS Foundation, London, UK
\textsuperscript{g} Centre for Age Related Research, Stavanger University Hospital, Stavanger, Norway
\textsuperscript{h} Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
\textsuperscript{i} Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
\textsuperscript{j} UK Dementia Research Institute at UCL, London, UK

\textbf{A R T I C L E  I N F O}

Article history:
Received 25 February 2021
Accepted 21 April 2021
Available online 4 May 2021

Keywords:
Plasma phosphorylated tau181
P-tau181
Plasma biomarkers
Genome wide association study

\textbf{A B S T R A C T}

Plasma phosphorylated tau at threonine-181 (P-tau181) demonstrates promise as an accessible blood-based biomarker specific to Alzheimer’s Disease (AD), with levels recently demonstrating high predictive accuracy for AD-relevant pathology. The genetic underpinnings of P-tau181 levels, however, remain elusive. This study presents the first genome-wide association study of plasma P-tau181 in a total sample of 1153 participants from 2 independent cohorts. No loci, other than those within the APOE genomic region (lead variant = rs429358, beta = 0.32, p = 8.44 × 10^{-25}) demonstrated association with P-tau181 at genome-wide significance (p < 5 × 10^{-8}), though rs60872856 on chromosome 2 came close (beta = -0.28, p = 3.23 × 10^{-07}, nearest gene=CYTIP). As the APOE ε4 allele is already a well-established genetic variant associated with AD, this study found no evidence of novel genetic associations relevant to plasma P-tau181, though presents rs60872856 on chromosome 2 as a candidate locus to be further evaluated in future larger size GWAS.

© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

1. Introduction

Plasma phosphorylated tau181 (P-tau181) is a promising blood-based biomarker that is highly specific for Alzheimer’s disease (AD) pathology. It correlates with cerebral Aβ and tau pathology (Karikari et al., 2020), is specifically associated with AD neuropathology (Lantero-Rodríguez et al., 2020) and predicts future cognitive decline (Karikari et al., 2021). It therefore has great potential for the diagnostic and prognostic evaluation of AD. Identifying genetic loci associated with plasma P-tau181 could help enhance understanding of specific components of AD pathophysiology, in particular, tau-associated pathology. To date, 2 GWAS on AD-relevant CSF endophenotypes (Cruchaga et al., 2013;
Deming et al., 2017] have identified 5 loci, including APOE, to be associated with CSF P-tau181. Recently, we investigated the relationship between AD polygenic risk scores (AD-PRS) and plasma P-tau181 (Zettergren et al., 2021). No GWAS on plasma P-tau181 levels have yet, however, been performed. Here, we present the first plasma P-tau181 GWAS, aiming to identify genetic loci associated with plasma P-tau181 levels and in turn, tau-associated pathology.

2. Materials and methods

932 participants from the Alzheimer’s Disease Neuroimaging initiative (ADNI) (http://www.adni-inof.org) and 228 participants from the European based AddNeuroMed (ANM) study (Lovestone et al., 2009) with available plasma P-tau181 and genotype data were utilised. Plasma P-tau181, for both ADNI and ANM cohorts, was measured using the Single-molecule array (Simoa) technology on an HDX Analyzer (Quanterix, Billerica, MA) (Karikari et al., 2021; Simrén et al., 2021). ADNI participants were genotyped across 3 genotyping platforms (Human610-Quad, HumanOniExpress and Omni 2.5M platforms). ANM participants were genotyped using the Human610-Quad genotyping platform. All chips underwent full quality control (QC), principal components (PCs) extraction and imputation in accordance with matched pipelines outlined within Supplementary Methods. Following QC, data across ADNI’s 3 genotyping platforms were merged, resulting in 2 cohorts of data – 1 from ADNI and 1 from ANM.

To maximise sample power, ADNI and ANM were each analysed separately before combining into a fixed-effects meta-analysis with betas weighted by the inverse of their variance. Plasma P-tau181 data was log_{10} transformed to approximate a normal distribution, and age, sex, and the first 7 PCs were controlled for within each study (Supplementary Methods). To correct for multiple testing, loci demonstrating evidence of an association at p < 5 × 10^{-08} were considered to show evidence of an association with P-tau181.

3. Results

Following QC, 932 ADNI and 221 ANM participants were retained (Supplementary Table 1). Meta-analysed results demonstrated a genome-wide significant association between plasma P-tau181 and the APOE genomic region (lead SNP: rs429358 (beta = 0.281, p = 2.54 × 10^{-25}) (Table 1, Supplementary Figure 1, Supplementary Table 4). No other loci reached genome-wide significance, though 1 chromosome 2 SNP within the CYTIP region (rs60872856) demonstrated an association at p < 5 × 10^{-07} (beta = 0.280, p = 3.23 × 10^{-07}) (Table 1, Supplementary Figures 1–2, Supplementary Table 4).

4. Discussion

Here, we present the first GWAS of plasma P-tau181, in a sample of 1,153 individuals from ADNI and ANM. rs429358 within the APOE genomic region demonstrated evidence of a genome-wide significant association with plasma P-tau181 (beta = 0.281, SE =0.027, p = 2.54 × 10^{-25}). No other loci reached genome-wide significance, though rs60872856 on chromosome 2 came close with a p-value of 3.23 × 10^{-07}. This chromosome 2 variant is located nearest to the cytohesin-interacting protein CYTIP region, a region involved in the regulation of immune response. None of the SNPs previously associated with CSF P-tau181 levels (Cruchaga et al., 2013; Deming et al., 2017) showed associations with plasma P-tau181 levels in this study.

The APOE ε4 allele is a well-established AD-associated genetic variant. Moreover, it has previously been shown to associate with AD-relevant pathology such as amyloid deposition, an event which is a precursor of elevated P-tau181 levels in the blood (Karikari et al., 2021). This study therefore identifies no evidence of novel genetic associations relevant to plasma P-tau181. It does, however, present rs60872856 on chromosome 2 as a candidate which may show promise in future, well-powered GWAS (Supplementary Results). As blood P-tau181 is an easily accessible and scalable blood biomarker, large-scale GWAS studies exceeding those of CSF biomarkers will be soon feasible.

Disclosure statement

KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectronics, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.

Acknowledgements

PP is an Alzheimer’s Research UK Senior Research Fellow (#ARUK-SRF2016A-3). JL is funded by the van Geest Endowment Fund. TKK holds a Brightfocus fellowship and is further supported by the Swedish Alzheimer Foundation (Alzheimerfonden), the Swedish Brain Foundation (Hjärnfonden), the Swedish Demen- tia Foundation (Dementförbundet), the Swedish Parkinson Foundation (Parkinsonfonden), Gamla Tjänarinnor, the Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation, the Gun and Bertil Stohnes Foundation, and the Anna Lisa and Brother Björnsson’s Foundation. KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPl-201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPD2019-466-236), and the National Institute of Health (NIH), USA, (grant #1R01AG08398-01). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the
AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. This paper represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.neurobiolaging.2021.04.015.

References

Cruchaga, C., Kauwe, J.S.K., Harari, O., Jin, S.C., Cai, Y., Karch, C.M., Benitez, B.A., Jeng, A.T., Skorupa, T., Carrell, D., Bertelsen, S., Bailey, M., McKean, D., Shulman, J.M., de Jager, P.L., Chibnik, L., Bennett, D.A., Arnold, S.E., Harold, D., Sims, R., Gerrish, A., Williams, J., Van Deerlin, V.M., Lee, V.M.Y., Shaw, L.M., Trojanowski, J.Q., Haines, J.L., Mayeux, R., Pericak-Vance, M.A., Farrer, L.A., Schellenberg, G.D., Peskind, E.R., Galasko, D., Fagan, A.M., Holtzman, D.M., Morris, J.C., Goate, A.M. Alzheimer Disease Genetic Consortium (ADGC), 2013. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease. Neuron 78, 256–268. doi:10.1016/j.neuron.2013.02.026.

Deming, Y., Li, Z., Kapoor, M., Harari, O., Del-Aguila, J.L., Black, K., Carrell, D., Cai, Y., Fernandez, M.V., Budde, J., Ma, S., Saej, B., Howells, B., Huang, K.-L., Bertelsen, S., Fagao, A.M., Holtzman, D.M., Morris, J.C., Kim, S., Saykin, A.J., de Jager, P.L., Albert, M., Moghekar, A., O’Brien, R., Riemenschneider, M., Petersen, R.C., Bellennow, K., Zetterberg, H., Minthon, L., Van Deerlin, V.M., Lee, V.M.Y., Shaw, L.M., Trojanowski, J.Q., Schellenberg, G., Haines, J.L., Mayeux, R., Pericak-Vance, M.A., Farrer, L.A., Peskind, E.R., Li, G., Di Nardo, A.F., Kauwe, J.S.K., Goate, A.M. Cruchaga C, Alzheimer Disease Genetic Consortium (ADGC), 2017. Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers. Acta Neuropathol. (Berl.) 133, 839–856. doi:10.1007/s00404-017-1695-y.

Karikari, T.K., Benedet, A.L., Ashton, N.J., Lantero Rodríguez, J., Snellman, A., Suárez-Calvet, M., Saha-Chaudhuri, P., Lussier, F., Kvarquist, H., Rial, A.M., Pascoal, T.A., Andreasson, U., Schöll, M., Weiner, M.W., Rosa-Neto, P., Trojanowski, J.Q., Shaw, L.M., Bellennow, K., Zetterberg, H. Alzheimer’s Disease Neuroimaging Initiative, 2021. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol. Psychiatry 26, 429–442. doi:10.1038/s41386-020-00923-z.

Karikari, T.K., Pascoal, T.A., Ashton, N.J., Janelidze, S., Benedet, A.L., Rodriguez, J.L., Chamoun, M., Savard, M., Kang, M.S., Therriault, J., Schöll, M., Massarweh, G., Soucy, J.P., Höglund, K., Brinkmalm, G., Mattsson, N., Palmpqvist, S., Gauthier, S., Stomrud, E., Zetterberg, H., Hansson, O., Rosa-Neto, P., Bellennow, K., 2020. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19, 422–433. doi:10.1016/S1474-7849(20)30071-5.

Lantero Rodríguez, J., Karikari, T.K., Suárez-Calvet, M., Troakes, C., King, A., Emerson, A., Aarsland, D., Hye, A., Zetterberg, H., Bellennow, K., Ashton, N.J., 2020. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. (Berl.) 140, 267–278. doi:10.1007/s00404-020-02195-x.

Simrén, J., Leuzy, A., Karikari, T.K., Hye, A., Benedet, A.L., Lantero-Rodriguez, J., Mattsson-Carlgren, N., Schöll, M., Meccoci, P., Vellas, B., Trolaki, M., Kloszweska, I., Soininen, H., Lovestone, S., Aarsland, D., consortium, AddNeuroMed, Hansson, O., Rosa-Neto, P., Westman, E., Bellennow, K., Zetterberg, H., Ashton, N.J., 2021. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. J. Alzheimers Assoc. doi:10.1007/s00404-022-02193-x.

Zettergren, A., Lord, J., Ashton, N.J., Benedet, A.L., Karikari, T.K., Lantero Rodríguez, J., Snellman, A., Suárez-Calvet, M., Prostis, P., Zetterberg, H., Bellennow, K. The Alzheimer’s Disease Neuroimaging Initiative1, 2021. Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Res. Ther. 13, 17. doi:10.1186/s13195-020-00754-8.